Global In-Vitro Toxicity Testing Markets & Technology Research Report 2022 with COVID-19 Impact Insights

News provided by

Feb 04, 2022, 09:45 ET

DUBLIN, Feb. 4, 2022 /PRNewswire/ -- The "In Vitro Toxicity Testing: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

This report examines the current and future market potential of In Vitro Toxicity Testing Technologies. It offers a detailed analysis of the competitive environment, the regulatory scenario, technological advancements, drivers, restraints, opportunity and trends in market growth.

This report covers market projections through 2026 and market rank for key market players. The report details the market shares of In Vitro Toxicity Testing Technologies segmented by toxicity endpoints and tests, tools/technology, components and end users.

The cost of animal testing is high, with some substances costing more than several million dollars. Along with the high cost of toxicity testing, animal welfare is another key concern that calls for alternative testing methods. In vitro model systems, like cell-based models, can significantly reduce costs and the use of animals in toxicity testing.

The increasing need for non-animal tests in toxicity testing is driving demand in the in vitro toxicity market. In vitro models are used to gain a better understanding of chemical-induced toxicity in animals and humans. The in vitro test model primarily serves as a rapid screening system for the toxicologic evaluation of chemicals. These models may complement in vivo toxicity tests or may replace some in vivo models if scientifically validated and accepted by regulatory agencies.

The most common in vitro models are isolated tissue preparations, perfused organ preparations, single-cell suspensions, and cell-culture systems (like primary cell cultures) and mammalian cell lines. Cell culture systems often are used because they are reliable, reproducible, and relatively inexpensive testing methods that assess chemical toxicity at the cellular level. Further, non-animal toxicity test methods have been used for determining cellular toxicity by manufacturers to support decisions for conducting conventional animal testing.

The growing demand for in vitro toxicity testing during the drug discovery process and increasing number of contract research organizations (CRO) are major drivers of the global in vitro toxicity market. The Developmental Therapeutics Program at the National Cancer Institute (DTP 2005) developed an in vitro cell-line screen to support its drug-discovery program.

For potential anticancer activity, the in vitro cell-line screen test can screen up to 20,000 compounds per year. The in vitro cell-line screen test uses 60 human tumor cell lines, representing various cancers such as skin cancer, breast cancer, colon cancer, brain cancer, prostate cancer, blood cancer, and kidney cancer.

Charles River, GVK Biosciences Private Ltd., Sekisui XenoTech LLC and Merck KGaA are among a large number of CROs that offer in vitro toxicity services. The increasing demand for animal-free toxicity tests driving the growth of the global in vitro toxicity market. In vitro toxicity tests are reliable, cost-effective and do not use animals, unlike in vivo tests.

The rising global prevalence of chronic diseases has significantly increased demand for the discovery of novel drugs. The toxicity study of drugs and compounds is performed by the regulatory bodies, in order to facilitate the approval of drugs and devices.

The high cost of toxicology equipment, inadequate infrastructure and funding for R&D in emerging countries are expected to hinder the growth of the global in vitro toxicity market. High-throughput screening (HTS) equipment is expensive, particularly for small and emerging countries that wish to purchase multiple instruments.

Their high cost may hinder market growth in these countries. However, governments, companies and research institutes are extensively funding for toxicology research, which should overcome the cost challenges and drive market growth during the forecast period.

Also, regulatory programs such as TOX21, ToxCast program and NTP (National Toxicology Program) are creating enormous opportunities for companies in the in vitro toxicity global market.

Report Includes

An updated review of the global markets for in vitro toxicity testing and technologies under development
Analyses of the global market trends, with data from 2019 to 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Technology assessment of the key drivers, restraints and opportunities that will shape the market for in vitro toxicity testing over the next five years (2021 to 2026)
Evaluation and forecast the overall market size, and corresponding market share analysis by toxicity endpoints and tests, tool/technology, component, end-user industry and geographic region
Highlights of COVID-19 implications on the progress of this market
Country specific data and market value analysis for the U.S., Canada, Mexico, Germany, U.K., France, Japan, China and India
Review of key technology developments, latest market trends, and other influential factors such as validation and testing strategies for pharmaceuticals, cosmetics and chemicals
Insight into recent industry structure, current competitive landscape, R&D activities, and regulatory and legislative issues currently focused on in vitro toxicology testing
Descriptive company profiles of the leading market players, including Abbott Laboratories Inc., GE Healthcare, PerkinElmer Inc., Qiagen NV and Thermo Fisher Scientific Inc.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Regulatory Framework and Programs

Medical Device Definition and Classification
Regulations
U.S.
Europe
Regulatory Timeline

Chapter 5 Market Dynamics

Market Dynamics
Market Drivers
Market Restraints
Opportunities

Chapter 6 Impact of COVID-19 Pandemic

Collaboration
Spread of Disease
Current Status and Impact on Medtech
Elective and Noncritical Procedures
Shift in Manufacturing
Regulatory Delays, Clinical Trials and Product Launches
Supply Chain Disruptions
Medical Tourism
Government and Private Funds
EUA for Diagnostic Kits and Devices
COVID-19: Global Landscape of Vaccine Development

Chapter 7 Market Breakdown by Toxicity Endpoint and Test

Global Market for In Vitro Toxicity by Toxicity Endpoint and Test
Market Size and Forecast
ADME
Genotoxicity Testing
Cytotoxicity Testing
Ocular Toxicity
Organ Toxicity
Skin Irritation, Corrosion and Sensitization
Phototoxicity Testing
Dermal Toxicity
Carcinogenicity
Neurotoxicity
Development and Reproductive Toxicity (DART)
Other Toxicity Endpoints and Tests

Chapter 8 Market Breakdown by Tool/Technology

Global Market for In Vitro Toxicity by Tool/Technology
Market Size and Forecast
Transcriptomics
Proteomics
Metabolomics
Cellomics or Cytomics

Chapter 9 Market Breakdown by Component

Equipment
Reagents and Kits
Software and Analytics
Services

Chapter 10 Market Breakdown by End User

Pharmaceutical and Biotechnology
Food and Beverage Industry
Healthcare (Diagnosis)
Chemical Industry
CROs
Research Institutes
Personal Care Products (Cosmetics)

Chapter 11 Market Breakdown by Region

North America
Europe
Asia-Pacific
Rest of the World

Chapter 12 Competitive Landscape

In Vitro Toxicity Testing
Global Company Share Analysis
In Vitro Toxicity Testing Market Players

Chapter 13 Company Profiles

Key Players
Abbott Laboratories, Inc.
Agilent Technologies Inc.
Ge Healthcare
Perkinelmer Inc.
Qiagen Nv
Thermo Fisher Scientific Inc.
Other Market Players
Acea Biosciences Inc.
Albany Molecular Research Inc.
Aptuit Inc.
Biognosys AG
Bioreliance
Biovia
Cellular Dynamics International Inc.
Chantest
Charles River Laboratories
Covance Inc.
Cyprotex plc
Drik LLC
Enzo Life Sciences Inc.
Essen Bioscience Inc.
Eurofins Scientific Se
Evotec AG
Genedata
Gentronix Ltd.
Hurel Corp.
Imquest Biosciences Inc.
Imstar Sa
Insphero AG
Kiyatec Inc.
Lonza Group Ltd.
Metabolon Inc.
Molecular Devices LLC
Promega Corp.
Sgs-Sa
Stemina Biomarker Discovery Inc.
Synvivo, Inc.
Vala Sciences Inc.
Vistagen Therapeutics Inc.
Xenometrix AG

For more information about this report visit https://www.researchandmarkets.com/r/cxc5oi

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets